Bioinvent International AB's next confirmed earnings release is scheduled for March 4, 2027.
| Earnings Date | 3/4/2027 |
As of September 30, 2026, Bioinvent International AB has 65.80M shares outstanding.
| Shares Outstanding | 65.80M |
As of September 30, 2026, Bioinvent International AB maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.80 |
| Quick Ratio | 2.33 |
| Debt / Equity | 9.62 |
| Debt / EBITDA | -0.04 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately 36,680.77 in revenue per employee across its workforce of 109.00, a quick read on workforce productivity versus industry peers.
| Revenue Per Employee | 36,680.77 |
| Employee Count | 109.00 |
Over the twelve months ended September 30, 2026, Bioinvent International AB recorded 41,500.04 in income tax expense. The company reported a pretax loss of -48.64M and -48.68M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | 41,500.04 |
As of the close on November 9, 2026, Bioinvent International AB's stock has declined approximately 91.49% over the past 52 weeks.
| 52-Week Price Change | -91.49% |
Over the twelve months ended September 30, 2026, Bioinvent International AB generated 4.00M in revenue and converted that into -48.68M in net income, yielding earnings per share of -0.74. EBITDA reached -47.85M, while operating income came in at -49.66M.
| Revenue | 4.00M |
| Operating Income | -49.66M |
| Pretax Income | -48.64M |
| Net Income | -48.68M |
| EBITDA | -47.85M |
| EBIT | -49.66M |
| Earnings Per Share (EPS) | -0.74 |
As of September 30, 2026, Bioinvent International AB holds 22.46M in cash and equivalents against 1.93M in total debt, resulting in a net debt position of -22.46M. Total book value stands at 20.09M, with working capital of 17.28M providing operational flexibility.
| Cash & Cash Equivalents | 22.46M |
| Total Debt | 1.93M |
| Net Debt | -22.46M |
| Equity (Book Value) | 20.09M |
| Book Value Per Share | 0.31 |
| Working Capital | 17.28M |
Bioinvent International AB produced -44.89M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -271,300.27 in capital expenditures, free cash flow totaled -45.16M - equivalent to -0.69 per share.
| Operating Cash Flow | -44.89M |
| Capital Expenditures | -271,300.27 |
| Free Cash Flow | -45.16M |
| FCF Per Share | -0.69 |
These figures cover the twelve months ended September 30, 2026. The operating margin of -1,242.18 and net profit margin of -1,217.66 provide insight into operational efficiency.
| Operating Margin | -1,242.18 |
| Pretax Margin | -1,216.62 |
| Profit Margin | -1,217.66 |
| EBITDA Margin | -1,196.87 |
Bioinvent International AB's most recent stock split took place on December 14, 2020 with a 25:1 split ratio.
| Last Split Date | 12/14/2020 |
| Split Ratio | 25:1 |
Already premium?